Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 8/20 | 0.43 |
| ▸ | TDO2 | P48775 | 8/20 | 0.43 |
| ▸ | DPP4 | P27487 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | SCN1A | P35498 | 3/20 | 0.40 |
| ▸ | SCN2A | Q99250 | 3/20 | 0.40 |
| ▸ | SCN3A | Q9NY46 | 3/20 | 0.40 |
| ▸ | IDO2 | Q6ZQW0 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27280965 | 0.75 | IDO1 (0.46) | IDO1TDO2DPP4TSHRF2 | |
| SCHEMBL127629 | 0.75 | IDO1 (0.46) | IDO1TDO2DPP4TSHRF2 | |
| Water SCHEMBL11878861 | 0.73 | IDO1 (0.44) | IDO1TDO2DPP4TSHRF2 | |
| Ammonia Solution, Strong SCHEMBL7282272 | 0.73 | IDO1 (0.44) | IDO1TDO2DPP4TSHRF2 | |
| Methane SCHEMBL29089947 | 0.73 | IDO1 (0.44) | IDO1TDO2DPP4TSHRF2 | |
| SCHEMBL13278769 | 0.72 | TSHR (0.50) | IDO1TDO2DPP4TSHRF2 | |
| SCHEMBL13279556 | 0.72 | HCAR2 (0.42) | DPP4TSHRF2LMNAADRA2A | |
| SCHEMBL303684 | 0.71 | IDO1 (0.43) | IDO1TDO2DPP4TSHRF2 | |
| SCHEMBL675765 | 0.71 | IDO1 (0.43) | IDO1TDO2DPP4TSHRF2 | |
| SCHEMBL9315772 | 0.71 | IDO1 (0.48) | IDO1TDO2DPP4TSHRF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1854877-B1 | Process for the deacylation of cyclic lipopeptides | ASTELLAS PHARMA INC (JP) | 2012-02-08 | — | — | EP | disclosed |
| EP-2172546-A1 | Process for the deacylation of cyclic lipopeptides | Astellas Pharma Inc. (JP) | 2010-04-07 | — | — | EP | disclosed |
| EP-0885957-B1 | PROCESS FOR THE DEACYLATION OF CYCLIC LIPOPEPTIDES | ASTELLAS PHARMA INC (JP) | 2009-08-12 | — | — | EP | disclosed |
| EP-1854877-A2 | Process for the deacylation of cyclic lipopeptides | Astellas Pharma Inc. (JP) | 2007-11-14 | — | — | EP | disclosed |
| EP-1666587-A1 | Cyclic lipopeptide acylase | Astellas Pharma Inc. (JP) | 2006-06-07 | — | — | EP | disclosed |
| US-6825003-B2 | Cyclic lipopeptide acylase | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-11-30 | — | — | US | disclosed |
| US-20040063959-A1 | Esters and amides as PLA2 inhibitors | FUKAMI NAOKI (JP) | 2004-04-01 | — | — | US | disclosed |
| US-6573084-B1 | Culture of Streptomyces anulatus 4811 (FERM BP-5808); deacylation of the lipid acyl moiety of FR-901379, Echinocandin B, and Aculeacin A | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-06-03 | — | — | US | disclosed |
| US-6537789-B1 | Using isolated acylase enzyme obtained from Streptomyces | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-03-25 | — | — | US | disclosed |
| US-20020169326-A1 | Esters and amides as PLA2 inhibitors | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 2002-11-14 | — | — | US | disclosed |
| WO-1997003951-A1 | ESTERS AND AMIDES AS PLA2 INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-02-06 | — | — | WO | disclosed |
| EP-0741697-A1 | AMINO ACID DERIVATIVES AND THEIR USE AS PHOSPHOLIPASE A2 INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-11-13 | — | — | EP | disclosed |
| US-5569646-A | TREATMENT OF PNEUMONIA; MICROBIOCIDES, FUNGICIDES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-10-29 | — | — | US | disclosed |
| EP-0462531-B1 | Cyclic polypeptide with antibiotic activity, process for its preparation and pure culture of a Coelomycetes strain | FUJISAWA PHARMACEUTICAL CO (JP) | 1996-10-02 | — | — | EP | disclosed |
| EP-0729974-A1 | Cyclic polypeptide with antibiotic activity and a process for preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-09-04 | — | — | EP | disclosed |
| WO-1995019959-A1 | AMINO ACID DERIVATIVES AND THEIR USE AS PHOSPHOLIPASE A2 INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-07-27 | — | — | WO | disclosed |
| EP-0644199-A1 | Cyclic antimicrobial peptides and preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-03-22 | — | — | EP | disclosed |
| US-5376634-A | Microbiocides | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-12-27 | — | — | US | disclosed |
| EP-0486011-A2 | Pharmaceutical composition against Pneumocystis carinii | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-05-20 | — | — | EP | disclosed |
| EP-0462531-A2 | Cyclic polypeptide with antibiotic activity, process for its preparation and pure culture of a Coelomycetes strain | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063959-A1 | Esters and amides as PLA2 inhibitors | PLA2G4A, PLA2G2D, PLA2G4B | IDO1 1086/4885TDO2 2515/4885DPP4 532/4885 |
| US-20020169326-A1 | Esters and amides as PLA2 inhibitors | PLA2G4A, PLA2G2D, PLA2G4B | IDO1 1163/4885TDO2 2582/4885DPP4 539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.